Evidence map›Paper›PMID 40122914›Full record

ArticleScientific reports2025

Contribution of 18 F-fluorocholine PET-CT to the preoperative localisation of parathyroid adenoma for the treatment of primary hyperparathyroidism.

Suzanne Garnier, Clémentine Mahéo, Gael Potard, Marie-Béatrice Cavarec, Nathalie Roudaut, Philippe Thuillier, Rémi Marianowski, Ronan Abgral, Jean-Christophe Leclere

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Cost-effectiveness of [¹¹C]Choline PET/CT as first-line imaging in primary hyperparathyroidism.European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Review
  4. Conventional imaging techniques plusFrontiers in endocrinology · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suzanne GarnierHead and Neck Surgery Department, CHU de Brest, Brest, 29200, France. suzanne.garnier@chu-brest.fr.
Clémentine MahéoHead and Neck Surgery Department, CHU de Brest, Brest, 29200, France.
Gael PotardHead and Neck Surgery Department, CHU de Brest, Brest, 29200, France.
Marie-Béatrice CavarecNuclear Medicine Department, CHU de Brest, Brest, 29200, France.
Nathalie RoudautEndocrinology Department, CHU de Brest, Brest, 29200, France.
Philippe ThuillierEndocrinology Department, CHU de Brest, Brest, 29200, France.
Rémi MarianowskiHead and Neck Surgery Department, CHU de Brest, Brest, 29200, France.
Ronan AbgralNuclear Medicine Department, CHU de Brest, Brest, 29200, France.
Jean-Christophe LeclereHead and Neck Surgery Department, CHU de Brest, Brest, 29200, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

18 F-fluorocholine PET-CT is considered a second-line method for the preoperative localisation of parathyroid adenomas in primary hyperparathyroidism. The aim was to compare the diagnostic performance of 18 F-fluorocholine PET-CT and standard imaging modalities in the preoperative localisation of parathyroid adenomas in primary hyperparathyroidism. The primary objective was to assess the performance of 18 F-fluorocholine PET-CT in cases of negative or discordant standard imaging. The secondary objective was to evaluate the diagnostic performance of both 18 F-fluorocholine PET-CT and standard imaging in relation to patient characteristics. We conducted a retrospective, monocentric study, including 156 patients who underwent parathyroidectomy between 2017 and 2023. All patients underwent preoperative 18 F-fluorocholine PET-CT and had an indication for surgery due to primary hyperparathyroidism. A total of 156 patients were included in the study, the majority of whom were women (78%). Seven patients had multigland disease (4.49%). Sensitivity was 60.14% for cervical ultrasound, 46.21% for [99mTc]-MIBI scintigraphy, and 95.97% for 18 F-Fluorocholine PET-CT. 18 F-Fluorocholine PET-CT showed a higher sensitivity than cervical ultrasound and [99mTc]-MIBI scintigraphy, especially for multiple parathyroid adenomas (100, 57.14, and 42.86%, respectively). Univariate analysis showed better results for cervical ultrasound in men (p = 0.005). Larger adenomas showed better performance on [99mTc]-MIBI scintigraphy (p = 0.026), and elevated PTH levels were associated with significantly worse performance on 18 F-fluorocholine PET-CT (p = 0.023). Multivariate analysis showed that scintigraphy performance was worse in the presence of thyroid nodules (p = 0.049, RR = 2.046, 95% CI 1.005-4.166). 18 F-fluorocholine PET-CT is a valuable imaging modality for the preoperative localisation of parathyroid adenomas in primary hyperparathyroidism, with superior performance compared to conventional imaging modalities. [99mTc]-MIBI scintigraphy showed reduced diagnostic performance in the presence of thyroid nodules.

Indexed as

AdenomaCholineHyperparathyroidism, PrimaryParathyroid NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedFemaleFluorine RadioisotopesHumansMaleMiddle AgedParathyroidectomyPreoperative CareRetrospective StudiesCholineFluorine Radioisotopesfluorocholine18F-Fluorocholine PET-CTParathyroid adenomaParathyroid scintigraphy.Primary hyperparathyroidism

Identifiers

PMID40122914
PMCPMC11930921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.